Evidence map›Paper›PMID 38759947›Full record

ReviewProgress in retinal and eye research2024

Alzheimer's disease pathophysiology in the Retina.

Bhakta Prasad Gaire, Yosef Koronyo, Dieu-Trang Fuchs, Haoshen Shi, Altan Rentsendorj, Ron Danziger, Jean-Philippe Vit, Nazanin Mirzaei, Jonah Doustar, Julia Sheyn and 19 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Progress in retinal and eye research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 67 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
67citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

67 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Visual field defects in dementia: A scoping review.Ophthalmic & physiological optics : the journal of the British College of Ophthalmic Opticians (Optometrists) · 2025
    Pooled it
  3. Pooled it
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Review
  15. Review
  16. Article
  17. Article
  18. Review
  19. Review
  20. Article

7 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

29 authors.

Bhakta Prasad GaireDepartment of Neurosurgery, Maxine Dunitz Neurosurgical Research Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Yosef KoronyoDepartment of Neurosurgery, Maxine Dunitz Neurosurgical Research Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Dieu-Trang FuchsDepartment of Neurosurgery, Maxine Dunitz Neurosurgical Research Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Haoshen ShiDepartment of Neurosurgery, Maxine Dunitz Neurosurgical Research Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Altan RentsendorjDepartment of Neurosurgery, Maxine Dunitz Neurosurgical Research Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Ron DanzigerDepartment of Neurology, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Jean-Philippe VitDepartment of Neurosurgery, Maxine Dunitz Neurosurgical Research Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Nazanin MirzaeiDepartment of Neurosurgery, Maxine Dunitz Neurosurgical Research Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Jonah DoustarDepartment of Neurosurgery, Maxine Dunitz Neurosurgical Research Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Julia SheynDepartment of Neurosurgery, Maxine Dunitz Neurosurgical Research Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Harald HampelSorbonne University, Alzheimer Precision Medicine (APM), AP-HP, Pitié-Salpêtrière Hospital, Paris, France.
Andrea VergalloSorbonne University, Alzheimer Precision Medicine (APM), AP-HP, Pitié-Salpêtrière Hospital, Paris, France.
Miyah R DavisDepartment of Neurosurgery, Maxine Dunitz Neurosurgical Research Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Ousman JallowDepartment of Neurosurgery, Maxine Dunitz Neurosurgical Research Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Filippo BaldacciSorbonne University, Alzheimer Precision Medicine (APM), AP-HP, Pitié-Salpêtrière Hospital, Paris, France; Department of Clinical and Experimental Medicine, Neurology Unit, University of Pisa, Pisa, Italy.
Steven R VerdoonerNeuroVision Imaging Inc., Sacramento, CA, USA.
Ernesto BarronDepartment of Ophthalmology, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA, USA; Doheny Eye Institute, Los Angeles, CA, USA.
Mehdi MirzaeiDepartment of Clinical Medicine, Health and Human Sciences, Macquarie Medical School, Macquarie University, Sydney, NSW, Australia.
Vivek K GuptaDepartment of Clinical Medicine, Health and Human Sciences, Macquarie Medical School, Macquarie University, Sydney, NSW, Australia.
Stuart L GrahamDepartment of Clinical Medicine, Health and Human Sciences, Macquarie Medical School, Macquarie University, Sydney, NSW, Australia; Department of Clinical Medicine, Macquarie University, Sydney, NSW, Australia.
Mourad TayebiSchool of Medicine, Western Sydney University, Campbelltown, NSW, Australia.
Roxana O CarareDepartment of Clinical Neuroanatomy, University of Southampton, Southampton, UK.
Alfredo A SadunDepartment of Ophthalmology, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA, USA; Doheny Eye Institute, Los Angeles, CA, USA.
Carol A MillerDepartment of Pathology Program in Neuroscience, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.
Oana M DumitrascuDepartment of Neurology, Mayo Clinic, Scottsdale, AZ, USA.
Shouri LahiriDepartment of Neurology, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Liang GaoDepartment of Bioengineering, University of California Los Angeles, Los Angeles, CA, USA.
Keith L BlackDepartment of Neurosurgery, Maxine Dunitz Neurosurgical Research Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Maya Koronyo-HamaouiDepartment of Neurosurgery, Maxine Dunitz Neurosurgical Research Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA; Department of Neurology, Cedars-Sinai Medical Center, Los Angeles, CA, USA; Department of Biomedical Sciences, Division of Applied Cell Biology and Physiology, Cedars-Sinai Medical Center, Los Angeles, CA, USA. Electronic address: maya.koronyo@csmc.edu.

Funding

Alzheimer's Disease Hallmark Pathology and Associated Inflammation in the RetinaR01AG055865 · NIA · CEDARS-SINAI MEDICAL CENTER · PI Maya Koronyo-Hamaoui · 2018 to 2026
$4.9M
The role of Chlamydia pneumoniae infection in Alzheimer's DiseaseR01AG075998 · NIA · CEDARS-SINAI MEDICAL CENTER · PI Timothy Robert Crother, Maya Koronyo-Hamaoui · 2021 to 2026
$3.7M
Retinal Imaging of Alzheimer's Disease PathologyR01AG056478 · NIA · CEDARS-SINAI MEDICAL CENTER · PI KORONYO-HAMAOUI, MAYA · 2017 to 2021
$2.5M
Vector Core Production Facility at Mount SinaiR24CA095833 · NCI · MOUNT SINAI SCHOOL OF MEDICINE OF NYU · PI WOO, SAVIO L · 2002 to 2006
$1.3M
A noninvasive optical imaging of retinal amyloid beta deposits in AD patientsR41AG044897 · NIA · NEUROVISION IMAGING, LLC · PI KORONYO-HAMAOUI, MAYA · 2013 to 2013
$151k
NCI NIH HHS R24 CA095833NIA NIH HHS R01 AG055865NIA NIH HHS R01 AG056478NIA NIH HHS R01 AG075998NIA NIH HHS R41 AG044897
6 · The paper itself

Abstract

The retina is an emerging CNS target for potential noninvasive diagnosis and tracking of Alzheimer's disease (AD). Studies have identified the pathological hallmarks of AD, including amyloid β-protein (Aβ) deposits and abnormal tau protein isoforms, in the retinas of AD patients and animal models. Moreover, structural and functional vascular abnormalities such as reduced blood flow, vascular Aβ deposition, and blood-retinal barrier damage, along with inflammation and neurodegeneration, have been described in retinas of patients with mild cognitive impairment and AD dementia. Histological, biochemical, and clinical studies have demonstrated that the nature and severity of AD pathologies in the retina and brain correspond. Proteomics analysis revealed a similar pattern of dysregulated proteins and biological pathways in the retina and brain of AD patients, with enhanced inflammatory and neurodegenerative processes, impaired oxidative-phosphorylation, and mitochondrial dysfunction. Notably, investigational imaging technologies can now detect AD-specific amyloid deposits, as well as vasculopathy and neurodegeneration in the retina of living AD patients, suggesting alterations at different disease stages and links to brain pathology. Current and exploratory ophthalmic imaging modalities, such as optical coherence tomography (OCT), OCT-angiography, confocal scanning laser ophthalmoscopy, and hyperspectral imaging, may offer promise in the clinical assessment of AD. However, further research is needed to deepen our understanding of AD's impact on the retina and its progression. To advance this field, future studies require replication in larger and diverse cohorts with confirmed AD biomarkers and standardized retinal imaging techniques. This will validate potential retinal biomarkers for AD, aiding in early screening and monitoring.

Indexed as

Alzheimer DiseaseRetinaRetinal DiseasesAmyloid beta-PeptidesAnimalsHumansRetinal VesselsTomography, Optical CoherenceAmyloid beta-PeptidesAlzheimer's diseaseInflammationNeurodegenerative diseasesRetinal imagingRetinal vascular pathologyVisual impairments

Identifiers

PMID38759947
PMCPMC11285518

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.